Strategic Growth DaVita Clinical Research has a track record of conducting over 500 clinical trials across more than 175 pharmaceutical companies, indicating a broad network and potential for expanding collaborations with sponsors seeking multi-specialty Phase II-III trial capabilities.

Kidney Care Focus Recent and historical partnerships in kidney care, including ASN Kidney Week presentations and the parent company’s kidney care leadership, position DCR as a preferred partner for nephrology-focused trials and related therapeutic areas.

Acquisition Momentum Historically active in M&A activity such as the MedSleuth acquisition and alliance networks, suggesting a growth-oriented mindset and potential for expanding site networks or adding clinical trial capabilities to accelerate study enrollment.

Digital & Compliance Readiness Adoption of a modern tech stack (OneTrust, Marketo, Sucuri, WordPress, Pendo) signals strong data privacy, marketing automation, and user experience capabilities, which can be leveraged to streamline sponsor onboarding, site management, and patient engagement.

Financial Scale With estimated revenue between 100M and 250M and a mid-sized employee base, DCR presents a cost-competitive option for sponsors seeking experienced Phase II-III CRO support without the scale of larger incumbents, potentially appealing to mid-to-large biopharma looking for flexibility and specialization.